ArticleBioengineered2022
Long non-coding RNA FAM230B is a novel prognostic and diagnostic biomarker for lung adenocarcinoma.
Article in Bioengineered, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 7 citations in OpenAlex.
- Decoding LncRNA in COPD: Unveiling Prognostic and Diagnostic Power and Their Driving Role in Lung Cancer Progression.International journal of molecular sciences · 2024Review
- Non-Coding RNAs in Kidney Stones.Biomolecules · 2024Review
- Exploring the Potential of Non-Coding RNAs as Liquid Biopsy Biomarkers for Lung Cancer Screening: A Literature Review.Cancers · 2023Review
- SLC8A1 antisense RNA 1 suppresses papillary thyroid cancer malignant progression via the FUS RNA binding protein (FUS)/NUMB like endocytic adaptor protein (Numbl) axis.Bioengineered · 2022Article
- Risk Model and Immune Signature of m7G-Related lncRNA Based on Lung Adenocarcinoma.Frontiers in genetics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Long non-coding RNA (lncRNA) FAM230B has been reported to participate in gastric cancer and papillary thyroid cancer, while its role in other cancers has not been reported. We then explored the role of FAM230B in lung adenocarcinoma (LA). This study enrolled a total of 60 LA patients, 60 patients with gastric reflux disease (GRD), 60 cases of chronic obstructive pulmonary disease (COPD), 60 cases of asthma and 60 cases of healthy controls. LA and paired non-tumor tissues were donated by all LA patients. Plasma samples were donated by all participants. Expression of FAM230B in these samples was determined by RT-qPCR. The 60 LA patients were followed up for 5 years to evaluate the prognostic value of plasma FAM230B for LA. Diagnostic value of FAM230B for LA was analyzed with ROC curve analysis. FAM230B was highly expressed in LA tissues compared to that in non-tumor samples. In addition, plasma FAM230B was specifically upregulated in LA patients, but not in GRD, COPD and asthma patients. High expression levels of FAM230B in plasma samples were closely correlated with poor survival. Plasma FAM230B effectively separated LA patients from GRD, COPD, asthma and control groups. Plasma FAM230B was closely correlated with tumor size, but not other clinical factors of LA patients. Therefore, FAM230B is highly upregulated in LA and may serve as a potential diagnostic and prognostic biomarker for LA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.